Advertisement

Clinical Modalities for the Diagnosis, Characterization and Detection of Bone Metastases

  • Michael H. Weber
  • Jonathan C. Sharp
  • Thomas H. Hassard
  • Martin Reed
  • James A. Thliveris
  • F. William Orr
Part of the Cancer Metastasis — Biology and Treatment book series (CMBT, volume 6)

Abstract

Breast cancer is a leading cause of death in women, occurring in one of eight during their lifetime. A comparable cancer in men, prostate cancer, claims the lives of just under 30,000 men in the United States each year with a prevalence of one in six (1). These tumors, along with carcinomas of the lung, thyroid, and kidney have a high propensity to metastasize to bone, which constitutes one of their most serious complications, creates a great challenge for treatment, and often carries a poor prognosis. Metastases are the most frequent bone tumors and cause significant morbidity due to pain, osteolysis, pathological fractures, hypercalcemia, and anemia (2). Established bone metastases are resistant to treatment and current therapeutic approaches such as endocrine therapy, radiation therapy, and chemotherapy are often ineffective (3). This chapter has been written on the premise that a better understanding of the pathophysiology of bone metastasis may provide insight into the design of diagnostic techniques that would help to identify bone metastasis formation at its earliest stages. This may provide an opportunity for early treatment and alleviate the necessity to treat them at a late stage.

Keywords

Prostate Cancer Bone Metastasis Prostate Specific Antigen Circulate Tumor Cell Bone Scintigraphy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, CA Cancer J Clin, 53: 5–26, 2003.PubMedGoogle Scholar
  2. 2.
    Rubens RD. Bone Metastases–The Clinical Problem. Eur J Cancer, 34: 210–213. 1998PubMedGoogle Scholar
  3. 3.
    Ratanatharathorn V, Powers WE, Moss WT, Perez CA. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys, 44: 1–18, 1999.PubMedGoogle Scholar
  4. 4.
    Vider M, Maruyama Y, Narvaez R. Significance of the vertebral venous (Batson’s) plexus in metastatic spread in colorectal carcinoma. Cancer, 40: 67–71, 1997.Google Scholar
  5. 5.
    Mathew P, Fleming D, Adegboyega PA. Myelophthisis as a solitary manifestation of failure from rectal carcinoma. A Batson phenomenon? Arch Pathol Lab Med, 124: 1228–1230, 2000.PubMedGoogle Scholar
  6. 6.
    Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140: 4451–4458, 1999.PubMedGoogle Scholar
  7. 7.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315–323, 1999.PubMedGoogle Scholar
  8. 8.
    Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem, 277: 24571–24578, 2002.PubMedGoogle Scholar
  9. 9.
    Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol, 20: 299–303, 2002.PubMedGoogle Scholar
  10. 10.
    Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer, 97 (Suppl 3): 779–784, 2003.PubMedGoogle Scholar
  11. 11.
    Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res, 5: 2372–2377, 1994.Google Scholar
  12. 12.
    Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW, Lang SH. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer, 86: 1136–1142, 2002.PubMedGoogle Scholar
  13. 13.
    Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst, 91: 1113–1124, 1999.PubMedGoogle Scholar
  14. 14.
    Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res, 3: 249–256, 1997.PubMedGoogle Scholar
  15. 15.
    Burkhardt R, Frisch B, Kettner G. The clinical study of micro-metastatic cancer by bone biopsy. Bull Cancer, 67: 291–305, 1980.PubMedGoogle Scholar
  16. 16.
    Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17–1A monoclonal antibodies. Proc Natl Acad Sci USA, 84: 8672–8676, 1987.PubMedGoogle Scholar
  17. 17.
    Brandt B, Roetger A, Heidl S, Jackisch C, Lelle RJ, Assmann G et al. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int J Cancer, 76: 824–828, 1998.PubMedGoogle Scholar
  18. 18.
    Muller P, Weckermann D, Riethmuller G, Schlimok G. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. Cancer Genet Cytogenet, 88: 8–16, 1996.PubMedGoogle Scholar
  19. 19.
    Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res, 7: 4080–4085, 2001.PubMedGoogle Scholar
  20. 20.
    Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res, 56: 4556–4561, 1996.PubMedGoogle Scholar
  21. 21.
    Sidransky D. Nucleic acid-based methods for the detection of cancer. Science, 278: 1054–1059, 1997.PubMedGoogle Scholar
  22. 22.
    Pantel K, Ahr A. Immunocytochemical and molecular strategies for the detection of micrometastases in patients with solid epithelial tumors: a review. Nucl Med Commun, 19: 521–527, 1998.PubMedGoogle Scholar
  23. 23.
    Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med, 342: 525–533, 2000.PubMedGoogle Scholar
  24. 24.
    Z’graggen K, Centeno BA, Fernandez-del Castillo C, Jimenez RE, Werner J, Warshaw AL. Biological implications of tumor cells in blood and bone marrow of pancreatic cancer patients. Surgery, 129: 537–546, 2001.PubMedGoogle Scholar
  25. 25.
    Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D et al. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer, 89: 8–13, 2000.PubMedGoogle Scholar
  26. 26.
    Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg, 232: 58–65, 2000.PubMedGoogle Scholar
  27. 27.
    Aoki S, Takagi Y, Hayakawa M, Yamaguchi K, Futamura M, Kunieda K et al. Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reactiontargeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients. J Exp Clin Cancer Res, 21: 555–562, 2002.Google Scholar
  28. 28.
    Austrup F, Uciechowski P, Eder C, Bockmann B, Suchy B, Driesel G et al. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer, 83: 1664–1673, 2000.PubMedGoogle Scholar
  29. 29.
    Khan ZA, Jonas SK, Le Marer N, Patel H, Wharton RQ, Tarragona A et al. P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res, 6: 3499–3504, 2000.PubMedGoogle Scholar
  30. 30.
    Zippelius A, Pantel K. RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci, 906: 110–123, 2000.PubMedGoogle Scholar
  31. 31.
    Ahr A, Scharl A, Muller M, von Minckwitz G, Gatje R, Pantel K et al. Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11. Int J Cancer, 84: 502–505, 1999.PubMedGoogle Scholar
  32. 32.
    Vlems FA, Diepstra JH, Cornelissen IM, Ruers TJ, Ligtenberg MJ, Punt CJ et al. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumor cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumor tissue. Mol Pathol, 55: 156–163, 2002.PubMedGoogle Scholar
  33. 33.
    Dimmler A, Gerhards R, Betz C, Gunther K, Reingruber B, Horbach T et al. Transcription of cytokeratins 8, 18, and 19 in bone marrow and limited expression of cytokeratins 7 and 20 by carcinoma cells: inherent limitations for RT-PCR in the detection of isolated tumor cells. Lab Invest, 81: 1351–1361, 2001.Google Scholar
  34. 34.
    Taback B, Chan AD, Kuo CT, Bostick PJ, Wang HJ, Giuliano AE et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res, 61: 8845–8850, 2001.PubMedGoogle Scholar
  35. 35.
    Kufer P, Zippelius A, Lutterbuse R, Mecklenburg I, Enzmann T, Montag A et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res, 62: 251–261, 2002.PubMedGoogle Scholar
  36. 36.
    Vogel I, Kruger U, Marxsen J, Soeth E, Kalthoff H, Henne-Bruns D et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res, 5: 593–599, 1999.PubMedGoogle Scholar
  37. 37.
    Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F et al. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res, 7: 4102–4108, 2001.PubMedGoogle Scholar
  38. 38.
    Cher ML, de Oliveira JG, Beaman AA, Nemeth JA, Hussain M, Wood DP, Jr. Cellular proliferation and prevalence of micrometastatic cells in the bone marrow of patients with clinically localized prostate cancer. Clin Cancer Res, 5: 2421–2425, 1999.PubMedGoogle Scholar
  39. 39.
    Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res, 59: 241–248, 1999.PubMedGoogle Scholar
  40. 40.
    Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA, 99: 2246–2251, 2002.PubMedGoogle Scholar
  41. 41.
    Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL et al. Prostate cancer and other xenografts from cells in peripheral blood of patients. Cancer Res, 60: 4033–4036, 2000.PubMedGoogle Scholar
  42. 42.
    Riethmuller G, Klein CA. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol, 11: 307–311, 2001.PubMedGoogle Scholar
  43. 43.
    Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst, 91: 80–85, 1999.PubMedGoogle Scholar
  44. 44.
    Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol, 19: 3669–3674, 2001.PubMedGoogle Scholar
  45. 45.
    Patel H, Le Marer N, Wharton RQ, Khan ZA, Araia R, Glover C et al. Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann Surg, 235: 226–231, 2002.PubMedGoogle Scholar
  46. 46.
    Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst, 85: 1419–1424, 1993.PubMedGoogle Scholar
  47. 47.
    Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol, 19: 960–971, 2001.PubMedGoogle Scholar
  48. 48.
    Funke I, Schraut W. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. J Clin Oncol, 16: 557–566, 1998.PubMedGoogle Scholar
  49. 49.
    Vogel I, Kalthoff H, Henne-Bruns D, Kremer B. Detection and prognostic impact of disseminated tumor cells in pancreatic carcinoma. Pancreatology, 2: 79–88, 2002.PubMedGoogle Scholar
  50. 50.
    Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol, 66: 699–703, 2001.Google Scholar
  51. 51.
    Jung R, Ahmad-Nejad P, Wimmer M, Gerhard M, Wagener C, Neumaier M. Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction. Eur J Clin Chem Clin Biochem, 35: 3–10, 1997.PubMedGoogle Scholar
  52. 52.
    Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U et al. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res, 57: 3106–3110, 1997.PubMedGoogle Scholar
  53. 53.
    Miyazono F, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K et al. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg, 233: 189–194, 2001.PubMedGoogle Scholar
  54. 54.
    Wharton RQ, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H et al. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res, 5: 4158–4163, 1999.PubMedGoogle Scholar
  55. 55.
    Aydiner A, Topuz E, Disci R, Yasasever V, Dincer M, Dincol K et al. Serum tumor markers for detection of bone metastasis in breast cancer patients. Acta Oncol, 33: 181–186, 1994.PubMedGoogle Scholar
  56. 56.
    Chigira M, Shinozaki T. Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas. Arch Orthop Trauma Surg, 109: 247–251, 1990.PubMedGoogle Scholar
  57. 57.
    Zanco P, Rota G, Sportiello V, Borsato N, Ferlin G. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques. Int J Biol Markers, 4: 103–105, 1989.PubMedGoogle Scholar
  58. 58.
    Francini G, Montagnani M, Petrioli R, Paffetti P, Marsili S, Leone V. Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers, 5: 65–72, 1990.PubMedGoogle Scholar
  59. 59.
    Suzuki S. Early diagnosis for bone metastasis of breast cancer based on bone metabolism. Fukushima J Med Sci, 36: 11–27, 1990.PubMedGoogle Scholar
  60. 60.
    Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology (Huntingt), 16: 1218–1224, 2002.Google Scholar
  61. 61.
    Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358–1368, 1994.PubMedGoogle Scholar
  62. 62.
    Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol, 70: 295–298, 1992.PubMedGoogle Scholar
  63. 63.
    O’Donoghue JM, Rogers E, Grimes H, McCarthy P, Corcoran M, Bredin H et al. A reappraisal of serial isotope bone scans in prostate cancer. Br J Radiol, 66: 672–676, 1993.PubMedGoogle Scholar
  64. 64.
    Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol, 155: 1348–1351, 1996.PubMedGoogle Scholar
  65. 65.
    Gundberg CM. Biochemical markers of bone formation. Clin Lab Med, 20: 489–501, 2000.PubMedGoogle Scholar
  66. 66.
    Looker AC, Bauer DC, Chesnut CH, III, Gundberg CM, Hochberg MC, Klee G et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int, 11: 467–480, 2000.PubMedGoogle Scholar
  67. 67.
    Hart SM, Eastell R. Biochemical markers of bone turnover. Curr Opin Nephrol Hypertens, 8: 421–427, 1999.PubMedGoogle Scholar
  68. 68.
    Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev, 22: 289–331, 1996.PubMedGoogle Scholar
  69. 69.
    Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer, 73: 1074–1079, 1996.PubMedGoogle Scholar
  70. 70.
    Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol, 12: 1433–1438, 2001.PubMedGoogle Scholar
  71. 71.
    Neri B, Gemelli MT, Sambataro S, Colombi L, Benvenuti F, Ludovici M et al. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs, 3: 87–90, 1992.PubMedGoogle Scholar
  72. 72.
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer, 82: 858–864, 2000.PubMedGoogle Scholar
  73. 73.
    Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat, 77: 245–252, 2003.PubMedGoogle Scholar
  74. 74.
    Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer, 103: 642–646, 2003.PubMedGoogle Scholar
  75. 75.
    Gunel N, Coskun U, Sancak B, Gunel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer, 95: 663–667, 2002.PubMedGoogle Scholar
  76. 76.
    Kiuchi K, Ishikawa T, Hamaguchi Y, Momiyama N, Hasegawa S, Ishiyama A et al. Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep, 9: 595–598, 2002.PubMedGoogle Scholar
  77. 77.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab, 79: 1693–1700, 1994.PubMedGoogle Scholar
  78. 78.
    Adami S. Bisphosphonates in prostate carcinoma. Cancer 1997, 80 (Suppl 8): 1674–1679.PubMedGoogle Scholar
  79. 79.
    Boland PJ, Lane JM, Sundaresan N. Metastatic disease of the spine. Clin Orthop, 169: 95–102, 1982.PubMedGoogle Scholar
  80. 80.
    Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans. J Nucl Med, 16: 986–989, 1975.PubMedGoogle Scholar
  81. 81.
    Subramanian G, McAfee JG. A new complex of 99mTc for skeletal imaging. Radiology, 99: 192–196, 1971.PubMedGoogle Scholar
  82. 82.
    Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer, 39: 1289–1294, 1997.Google Scholar
  83. 83.
    Hermann G, Herman P. Computerized tomography of the spine in metastatic disease. Mt Sinai J Med, 49: 400–405, 1982.PubMedGoogle Scholar
  84. 84.
    Swanson DA, Bernardino ME. “Silent” osseous metastases in renal cell carcinoma: value of computerized tomography. Urology, 20: 208–212, 1982.PubMedGoogle Scholar
  85. 85.
    Helms CA, Cann CE, Brunelle FO, Gilula LA, Chafetz N, Genant HK. Detection of bone-marrow metastases using quantitative computed tomography. Radiology, 140: 745–750, 1981.PubMedGoogle Scholar
  86. 86.
    Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop, 312: 64–75, 1995.PubMedGoogle Scholar
  87. 87.
    Body JJ. Metastatic bone disease: clinical and therapeutic aspects. Bone, 13 (Suppl 1): S57 - S62, 1992.PubMedGoogle Scholar
  88. 88.
    Jacobsson H, Goransson H. Radiological detection of bone and bone marrow metastases. Med Oncol Tumor Pharmacother, 8: 253–260, 1991.PubMedGoogle Scholar
  89. 89.
    Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol, 18 (Suppl 5): 11–15, 1991.PubMedGoogle Scholar
  90. 90.
    Coombes RC, Dady P, Parsons C, McCready VR, Ford HT, Gazet JC et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer, 52: 610–614, 1983.PubMedGoogle Scholar
  91. 91.
    Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med, 29: 1354–1359, 1988.PubMedGoogle Scholar
  92. 92.
    Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol, 13: 1123–1128, 1995.PubMedGoogle Scholar
  93. 93.
    Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med, 45: 53–64, 2001.PubMedGoogle Scholar
  94. 94.
    Walker RE, Eustace SJ. Whole-body magnetic resonance imaging: techniques, clinical indications, and future applications. Semin Musculoskelet Radiol, 5: 5–20, 2001.PubMedGoogle Scholar
  95. 95.
    Azouz EM. Magnetic resonance imaging of benign bone lesions: cysts and tumors. Top Magn Reson Imaging, 13: 219–229, 2002.PubMedGoogle Scholar
  96. 96.
    Gold RI, Seeger LL, Bassett LW, Steckel RJ. An integrated approach to the evaluation of metastatic bone disease. Radiol Clin North Am, 28: 471–483, 1990.PubMedGoogle Scholar
  97. 97.
    Bloem JL, Algra PR. Imaging of osseous metastases. Acta Clin Belg Suppl, 15: 43–46, 1993.PubMedGoogle Scholar
  98. 98.
    Traill Z, Richards MA, Moore NR. Magnetic resonance imaging of metastatic bone disease. Clin Orthop, 312: 76–88, 1995.PubMedGoogle Scholar
  99. 99.
    Kattapuram SV, Khurana JS, Scott JA, el-Khoury GY. Negative scintigraphy with positive magnetic resonance imaging in bone metastases. Skeletal Radiol, 19: 113–116, 1990.PubMedGoogle Scholar
  100. 100.
    Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol, 177: 229–236, 2001.Google Scholar
  101. 101.
    Colletti PM, Dang HT, Deseran MW, Kerr RM, Boswell WD, Ralls PW. Spinal MR imaging in suspected metastases: correlation with skeletal scintigraphy. Magn Reson Imaging, 9: 349–355, 1991.PubMedGoogle Scholar
  102. 102.
    Nishimura R, Nagao K, Miyayama H, Yasunaga T, Asao C, Matsuda M et al. Diagnostic problems of evaluating vertebral metastasis from breast carcinoma with a higher degree of malignancy. Cancer, 85: 1782–1788, 1999.PubMedGoogle Scholar
  103. 103.
    Savelli G, Chiti A, Grasselli G, Maccauro M, Rodari M, Bombardieri E. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res, 20: 1115–1120, 2002.Google Scholar
  104. 104.
    Kosuda S, Kaji T, Yokoyama H, Yokokawa T, Katayama M, Iriye T et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J Nucl Med, 37: 975–978, 1996.PubMedGoogle Scholar
  105. 105.
    Jones KM, Schwartz RB, Mantello MT, Ahn SS, Khorasani R, Mukherji S et al. Fast spin-echo MR in the detection of vertebral metastases: comparison of three sequences. AJNR Am J Neuroradiol, 15: 401–407, 1994.PubMedGoogle Scholar
  106. 106.
    Weber MH, Sharp JC, Hassard TH, Orr FW. Normal murine bone morphometry: a comparison of magnetic resonance microscopy with micro X-ray and histology. Skeletal Radiol, 31: 282–291, 2002.PubMedGoogle Scholar
  107. 107.
    Schweitzer ME, Levine C, Mitchell DG, Gannon FH, Gomella LG. Bull’s-eyes and halos: useful MR discriminators of osseous metastases. Radiology, 188: 249–252, 1993.PubMedGoogle Scholar
  108. 108.
    Uchida N, Sugimura K, Kajitani A, Yoshizako T, Ishida T. MR imaging of vertebral metastases: evaluation of fat saturation imaging. Eur J Radiol, 17: 91–94, 1993.PubMedGoogle Scholar
  109. 109.
    Mirowitz SA, Apicella P, Reinus WR, Hammerman AM. MR imaging of bone marrow lesions: relative conspicuousness on T1-weighted, fat-suppressed T2-weighted, and STIR images. AJR Am J Roentgenol, 162: 215–221, 1994.PubMedGoogle Scholar
  110. 110.
    Castillo M, Arbelaez A, Smith JK, Fisher LL. Diffusion-weighted MR imaging offers no advantage over routine noncontrast MR imaging in the detection of vertebral metastases. AJNR Am J Neuroradiol, 21: 948–953, 2000.PubMedGoogle Scholar
  111. 111.
    Engelke K, Majumdar S, Genant HK. Phantom studies simulating the impact of trabecular structure on marrow relaxation time, T2’. Magn Reson Med, 31: 380–387, 1994.PubMedGoogle Scholar
  112. 112.
    Majumdar S, Genant HK. In vivo relationship between marrow T2’ and trabecular bone density determined with a chemical shift-selective asymmetric spin-echo sequence. J Magn Reson Imaging, 2: 209–219, 1992.Google Scholar
  113. 113.
    Engelke K, Hahn M, Takada M, Vogel M, Ouyang X, Delling G et al. Structural analysis of high resolution in vitro MR images compared to stained grindings. Calcif Tissue Int, 68: 163–171, 2001.PubMedGoogle Scholar
  114. 114.
    Link TM, Majumdar S, Augat P, Lin JC, Newitt D, Lane NE et al. Proximal femur: assessment for osteoporosis with T2’ decay characteristics at MR imaging. Radiology, 209: 531–536, 1998.PubMedGoogle Scholar
  115. 115.
    Amano Y, Hayashi H, Kumazaki T. Gd-DTPA enhanced MRI of reactive hematopoietic regions in marrow. J Comput Assist Tomogr, 18: 214–217, 1994.PubMedGoogle Scholar
  116. 116.
    Van der Woude HJ, Egmont-Petersen M. Contrast-enhanced magnetic resonance imaging of bone marrow. Semin Musculoskelet Radiol, 5: 21–33, 2001.PubMedGoogle Scholar
  117. 117.
    Seneterre E, Weissleder R, Jaramillo D, Reimer P, Lee AS, Brady TJ et al. Bone marrow: ultrasmall superparamagnetic iron oxide for MR imaging. Radiology, 179: 529–533, 1991.PubMedGoogle Scholar
  118. 118.
    Daldrup-Link HE, Rummeny EJ, Ihssen B, Kienast J, Link TM. Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin’s lymphoma: differentiation between tumor infiltration and hypercellular bone marrow. Eur Radiol, 12: 1557–1566, 2002.PubMedGoogle Scholar
  119. 119.
    Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci, 5: 75–81, 2000.PubMedGoogle Scholar
  120. 120.
    Noguchi M, Kikuchi H, Ishibashi M, Noda S. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer, 88: 195–201, 2003.PubMedGoogle Scholar
  121. 121.
    Meijer WG, van d, V, Jager PL, van der Jagt EJ, Piers BA, Kema IP et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med, 44: 184–191, 2003.PubMedGoogle Scholar
  122. 122.
    Rydh A, Lundblad M, Ahlstrom KR, Tavelin B, Stattin P. MRI of the skeleton in prostate cancer staging. Scand J Urol Nephrol, 37: 222–225, 2003.PubMedGoogle Scholar
  123. 123.
    Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer, 97 (Suppl 3): 874–879, 2003.PubMedGoogle Scholar
  124. 124.
    Hou MF, Lin SB, Yuan SS, Tsai LY, Tsai SM, Hsieh JS et al. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients. Ann Clin Lab Sci, 33: 55–61, 2003.PubMedGoogle Scholar
  125. 125.
    Behrens P, Bruns J, Ullrich KP, Acil Y, Gille J. Pyridinoline cross-links as markers for primary and secondary bone tumors. Scand J Clin Lab Invest, 63: 37–44, 2003.PubMedGoogle Scholar
  126. 126.
    Okamura T, Akita H, Tatsura H, Kawai N, Nagata D, Azemoto M et al. The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies. Cancer Detect Prev, 27: 14–18, 2003.PubMedGoogle Scholar
  127. 127.
    Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer, 94: 2521–2533, 2002.PubMedGoogle Scholar
  128. 128.
    Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res, 5: 3914–3919, 1999.PubMedGoogle Scholar
  129. 129.
    Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res, 15: 1337–1345, 2000.PubMedGoogle Scholar
  130. 130.
    Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol, 20: 850–856, 2002.PubMedGoogle Scholar
  131. 131.
    Nakashima J, Ozu C, Nishiyama T, Oya M, Ohigashi T, Asakura H et al. Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy. Urology, 56: 843–847, 2000.PubMedGoogle Scholar
  132. 132.
    Yorio MA, Sembaj A, Sanz E, Carriazo C, Moreno BJ. Alkaline phosphatase isoenzymes for the diagnosis of metastatic tumors and lymphomas of liver and bone. Medicina (B Aires), 60: 311–315, 2000.Google Scholar
  133. 133.
    Smith R, Lange R. Understanding magnetic resonance imaging. New York: CRC Press., 1998.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • Michael H. Weber
    • 1
    • 4
  • Jonathan C. Sharp
    • 4
  • Thomas H. Hassard
    • 2
  • Martin Reed
    • 5
  • James A. Thliveris
    • 3
  • F. William Orr
    • 1
  1. 1.The Department of PathologyUniversity of ManitobaWinnipegCanada
  2. 2.Department of Community Health ScienceUniversity of ManitobaWinnipegCanada
  3. 3.Department of Human Anatomy and Cell ScienceCanada
  4. 4.Institute for BiodiagnosticsNational Research Council of CanadaWinnipegCanada
  5. 5.The Department of RadiologyHealth Sciences CentreWinnipegCanada

Personalised recommendations